The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.
This study assessed BGB-16673, an investigational drug that degrades the BTK protein, in 60 patients with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who had received multiple prior treatments. BGB-16673 was generally well tolerated. The most common TEAEs in either group were fatigue and neutropenia. TEAEs led to 1 treatment discontinuation in the FL group and 5 in the MZL group, and 1 death due to intracranial hemorrhage occurred in the MZL group. In 48 response-evaluable patients, the overall response rate was 41% (7/17) for FL, and 55% (17/31) for MZL, including among patients previously treated with BTK inhibitors. Some patients achieved complete responses, and many remained on treatment. These results support further study of BGB-16673 for these lymphoma subtypes.
